Some patients, for example, might experience diminished response to anti-TNF drugs over time or develop a paradoxical exacerbation of PsO (27); similar cases of paradoxical psoriasis have been reported for secukinumab (anti–IL-17 monoclonal antibody) and ustekinumab (IL-12/23 inhibitor) (28, 29). Here, IL17A is linked to psoriasis.